metformin has been researched along with liraglutide in 208 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (2.88) | 29.6817 |
| 2010's | 143 (68.75) | 24.3611 |
| 2020's | 59 (28.37) | 2.80 |
| Authors | Studies |
|---|---|
| Filipczak, R; Gumprecht, J; Hompesch, M; Le, TD; Nauck, MA; Zdravkovic, M | 1 |
| Düring, M; Frid, A; Hermansen, K; Matthews, DR; Mitha, IH; Nauck, M; Shah, NS; Tankova, T; Zdravkovic, M | 1 |
| Blonde, L; Buse, JB; Gerich, J; Hale, PM; Lewin, A; Raskin, P; Schwartz, S; Zdravkovic, M; Zinman, B | 1 |
| Mannucci, E; Marchionni, N; Monami, M | 1 |
| Antic, S; Lalic, N; Ravn, GM; Russell-Jones, D; Schmitz, O; Sethi, BK; Simó, R; Vaag, A; Zdravkovic, M | 1 |
| Jahn, E; Sausele, T | 1 |
| Brown, A; Desai, M; Taneja, D; Tannock, LR | 1 |
| Bailey, T; Cuddihy, R; Davies, M; Filetti, S; Montanya, E; Nauck, M; Pratley, RE; Søndergaard, RE; Thomsen, AB | 1 |
| Hammer, M; Hermansen, K; Kolotkin, RL; Matthews, D; Zdravkovic, M | 1 |
| Campbell, RK; Cobble, ME; Reid, TS; Shomali, ME | 5 |
| Schmidt, WE | 1 |
| Bech, OM; Bhattacharyya, A; Chen, L; Ji, Q; Kim, KW; Kumar, A; Liu, X; Ma, J; Tandon, N; Yang, W; Yoon, KH; Zychma, M | 1 |
| Conner, C; Hammer, M; Lee, WC | 1 |
| Cuddihy, R; Davies, M; Hammer, M; Pratley, R; Thomsen, AB | 1 |
| Bailey, T; Cuddihy, R; Davies, M; Filetti, S; Garber, A; Hartvig, H; Montanya, E; Nauck, M; Pratley, R; Thomsen, AB | 1 |
| Cyganek, K; Koblik, T; Kozek, E; Malecki, MT; Starzyk, J; Wojcik, M | 1 |
| Freeman, JS | 1 |
| Cummins, E; Royle, P; Shyangdan, D; Waugh, N | 1 |
| Chubb, BD; Davies, MJ; Smith, IC; Valentine, WJ | 1 |
| Barboza, J; Sando, KR; Taylor, J; Willis, C | 1 |
| Jermendy, G | 1 |
| Anders, S; Forst, T; Michelson, G; Mitry, M; Pfützner, A; Ratter, F; Weber, MM; Wilhelm, B | 1 |
| Corsi, A; Ponzani, P | 1 |
| Nauck, MA | 1 |
| Gough, SC | 1 |
| Bain, SC; D'Alessio, D; DeVries, JH; Rodbard, HW; Rosenstock, J; Seufert, J; Thomsen, AB; Zychma, M | 1 |
| Langer, J; Lee, WC; Palmer, JL; Samyshkin, Y | 1 |
| Bailey, T; Davies, M; Filetti, S; Furber, S; Garber, AJ; Montanya, E; Nauck, MA; Pratley, RE; Thomsen, AB | 1 |
| During, M; Frid, A; Hermansen, K; Matthews, DR; Mitha, I; Nauck, M; Shah, N; Tankova, T; Thomsen, AB | 1 |
| Gao, L; Li, SC; Zhao, FL | 1 |
| Giulietti, A; Giusti, L; Mazzanti, L; Nanetti, L; Provinciali, L; Raffaelli, F; Vignini, A | 1 |
| Coester, HV; Forst, T; Hincelin-Méry, A; Kapitza, C; Poitiers, F; Ruus, P | 1 |
| Ortúzar, N | 1 |
| Hunt, B; Langer, J; Valentine, WJ | 1 |
| Charbonnel, B; Davies, MJ; Engel, SS; Eymard, E; Prabhu, V; Steinberg, H; Thakkar, P; Xu, L | 1 |
| Buse, JB; Kahn, SE; Krause-Steinrauf, H; Lachin, JM; Larkin, ME; Nathan, DM; Staten, M; Wexler, D | 1 |
| Bailey, T | 1 |
| Lüdemann, J | 1 |
| Chan, KA; Funch, D; Gydesen, H; Major-Pedersen, A; Tornøe, K | 1 |
| Janez, A; Jensterle Sever, M; Kocjan, T; Kravos, NA; Pfeifer, M | 1 |
| Brady, EM; Davies, MJ; Gray, LJ; Hanif, W; Khunti, K; Saeed, MA; Smith, D | 1 |
| Batchuluun, B; Fujimura, Y; Inoguchi, T; Inoue, T; Miura, D; Sasaki, S; Sonoda, N; Takayanagi, R | 1 |
| Cariou, B; Handelsman, Y; Mathieu, C; Ocampo Francisco, AM; Philis-Tsimikas, A; Rana, A; Rodbard, HW; Zinman, B | 1 |
| Fernández-García, JC; Gómez-Pérez, AM; Mancha Doblas, I; Tinahones, FJ | 1 |
| Breitschaft, A; Darstein, C; Golor, G; Hermosillo Reséndiz, K; Hu, K | 1 |
| Ding, M; Li, CJ; Liu, XJ; Yu, DM; Yu, P; Yu, Q; Zhang, QM | 1 |
| Beiroa, D; Dieguez, C; Escalada, J; Fernø, J; Frühbeck, G; Gallego, R; Herranz, D; Imbernon, M; Lopez, M; Nogueiras, R; Salvador, J; Senra, A; Serrano, M; Villarroya, F | 1 |
| Persson, U; Steen Carlsson, K | 1 |
| Atisso, C; Dungan, KM; Fahrbach, JL; Forst, T; González, JG; Povedano, ST; Sealls, W | 1 |
| Anholm, C; Haugaard, SB; Klit, MS; Kristiansen, OP; Kumarathurai, P; Ladelund, S; Madsbad, S; Nielsen, OW; Sajadieh, A | 1 |
| Blevins, TC; Buse, JB; Bøttcher, SG; Langbakke, IH; Rodbard, HW; Thurman, J; Vilsbøll, T | 1 |
| Buse, JB; Diamant, M; Donsmark, M; Furber, S; Han, J; MacConell, L; Maggs, D; Peters, A; Russell-Jones, D | 1 |
| Candelas, C; Charbonnel, B; D'Alessio, D; Dain, MP; de Pablos-Velasco, P; Häring, HU; Pilorget, V; Vincent, M; Yki-Järvinen, H | 1 |
| Abate, N; Banach, M; Barbagallo, I; Chandalia, M; Giglio, RV; Isenovic, ER; Li Volti, G; Marino Gammazza, A; Montalto, G; Nikolic, D; Rizvi, AA; Rizzo, M | 1 |
| Bueno, M; Lecube, A; Suárez, X | 1 |
| Abegg, K; Boza, C; Corteville, C; Docherty, NG; le Roux, CW; Lutz, TA; Muñoz, R | 1 |
| Thompson, AM; Trujillo, JM | 1 |
| Buturovic, BA; Narancic, AM; Ristic, LB | 1 |
| Balzano, S; Bax, G; Bettio, M; Bonsembiante, B; Brun, E; Cardone, C; Confortin, L; D'Ambrosio, M; Da Tos, V; Dal Frà, MG; Dal Pos, M; Ferrari, M; Frison, V; Gallo, A; Lamonica, M; Lapolla, A; Marangoni, A; Marin, N; Masin, M; Mesturino, CA; Panebianco, G; Pianta, A; Piarulli, F; Rocchini, P; Sartore, G; Simioni, N; Simoncini, M; Strazzabosco, M; Tadiotto, F; Zen, F | 1 |
| Atsumi, Y; Imai, T; Irie, J; Itoh, H; Kawai, T; Meguro, S; Morimoto, J; Saisho, Y; Shigihara, T; Takei, I; Tanaka, K; Tanaka, M; Yajima, K | 1 |
| Castel, H; Chartrand, G; Chiasson, JL; de Guise, J; Gilbert, G; Julien, AS; Massicotte-Tisluck, K; Olivié, D; Rabasa-Lhoret, R; Soulez, G; Tang, A; Wartelle-Bladou, C | 1 |
| Brunetti, A; Capula, C; Chiefari, E; Foti, D; Greco, M; Liguori, R; Oliverio, R; Puccio, L; Pullano, V; Tirinato, D; Vero, A; Vero, R | 1 |
| Coester, HV; Delfolie, A; Forst, T; Hincelin-Méry, A; Kapitza, C; Meier, JJ; Menge, BA; Rosenstock, J; Roy-Duval, C | 1 |
| Blann, AD; Gupta, PS; Ryder, RE; Thong, KY | 1 |
| Bode, BW; Buse, JB; Gough, SC; Linjawi, S; Reiter, PD; Rodbard, HW; Woo, VC; Zacho, M | 1 |
| Janez, A; Jensterle, M; Kocjan, T; Salamun, V; Vrtacnik Bokal, E | 1 |
| Agha, A; Ashley, DT; Cummins, PM; Davenport, C; Forde, H; Mahmood, WA; McAdam, B; McDermott, J; McGrath, F; Smith, D; Sreenan, S; Thompson, CJ | 1 |
| Ahmann, A; Boopalan, A; de Loredo, L; Lahtela, JT; Nauck, MA; Rodbard, HW; Rosenstock, J; Tornøe, K | 1 |
| Chen, C; Chen, P; Huang, Q; Shao, Z; Wang, S; Xu, X; Yan, L | 1 |
| Buse, JB; Gough, SC; Kvist, K; Langbakke, IH; Rodbard, HW; Vilsbøll, T; Woo, V | 1 |
| Dungan, KM; Fahrbach, JL; Raz, I; Sealls, W; Skrivanek, Z | 1 |
| Chen, L; Chen, R; Liu, Y; Ma, Z; Yu, P | 1 |
| Cobelli, C; Irie, J; Itoh, H; Jinzaki, M; Kawai, T; Manesso, E; Meguro, S; Saisho, Y; Sugiura, H; Tanaka, K; Tanaka, M | 1 |
| Carbone, MD; De Pergola, G; Giagulli, VA; Guastamacchia, E; Licchelli, B; Ramunni, MI; Sabbà, C; Triggiani, V | 1 |
| Solis-Herrera, C; Triplitt, C | 1 |
| Ferrario, MG; Lizán, L; Montagnoli, R; Ramírez de Arellano, A | 1 |
| Tong, N; Zhang, L; Zhang, M; Zhang, Y | 1 |
| Bosch-Traberg, H; Kaku, K; Kaneko, S; Kiyosue, A; Nishijima, K; Ono, Y; Seino, Y; Shiraiwa, T | 1 |
| García Díaz, E; Godoy, T; Guagnozzi, D; Gutiérrez, V; Larrañaga, Y; Maza, C; Mendoza, C; Perdomo, D; Taleb, G | 1 |
| Geurin, MD | 1 |
| Andersen, TH; Aroda, VR; Bailey, TS; Cariou, B; Kumar, S; Leiter, LA; Philis-Tsimikas, A; Raskin, P; Zacho, J | 1 |
| Bian, F; Bosch-Traberg, H; Geng, J; Li, Y; Liu, J; Liu, Y; Luo, Y; Lv, X; Mu, Y; Peng, Y; Sun, Y; Yang, J; Zang, L | 1 |
| Boucheron, JA; Gillmor, DS; Hodge, RJ; McMullen, SL; Nunez, DJ; Paulik, MA; Walker, A | 1 |
| Chen, C; Chen, P; Guo, W; Huang, LH; Huang, Q; Li, CM; Shao, ZL; Xu, XJ; Yang, XZ | 1 |
| Farooq, S; Islam, N; Kiran, Z; Rashid, O | 1 |
| Diéguez, C; López, M; Nogueiras, R; Tena-Sempere, M | 1 |
| Li, Y; Liu, G; Liu, S; Tian, M; Wang, Y; Zhang, X | 1 |
| Bosch-Traberg, H; Cariou, B; Johnson, A; Madsen, J; Nauck, M; Rizzo, M | 1 |
| Li, ZX; Sun, F; Wu, SS; Yang, ZR; Zhan, SY | 1 |
| Al Araj, S; Azar, ST; Berrah, A; Echtay, A; Kaltoft, MS; Mutha, A; Omar, M; Shehadeh, N; Tornøe, K; Wan Bebakar, WM | 1 |
| Bailey, TS; Kaltoft, MS; Maislos, M; Rao, PV; Takács, R; Thomsen, AB; Tinahones, FJ; Tsoukas, GM | 1 |
| Cahen, DL; Diamant, M; Groen, AK; Hoekstra, T; Kramer, MH; Muskiet, MH; Nieuwdorp, M; Smits, MM; Tonneijck, L; van Raalte, DH | 1 |
| Gu, J; Guo, Y; Liu, Y; Meng, X; Wang, D; Wang, L; Wu, B; Zheng, H | 1 |
| Bobart, SA; Gleason, B; Martinez, N; Norris, K; Williams, SF | 1 |
| Baranov, O; Deacon, CF; Holst, JJ; Kahle, M; Nauck, MA | 1 |
| Diamant, M; Hoekstra, T; Kramer, MH; Muskiet, MH; Smits, MM; Tonneijck, L; van Raalte, DH | 1 |
| Anholm, C; Haugaard, SB; Kristiansen, O; Kumarathurai, P; Larsen, BS; Madsbad, S; Nielsen, OW; Olsen, RH; Sajadieh, A | 1 |
| Abd El Aziz, MS; Bettge, K; Kahle, M; Meier, JJ; Nauck, MA | 1 |
| Caprio, M; Castellino, G; Ceriello, A; Genovese, S; Giglio, RV; Li Volti, G; Montalto, G; Nikolic, D; Patti, AM; Provenzano, V; Rizvi, AA; Rizzo, M | 1 |
| Banga, PK; Bianco, SD; Iacobellis, G; Mohseni, M | 1 |
| Anholm, C; Fabricius-Bjerre, A; Haugaard, SB; Kristiansen, O; Kumarathurai, P; Madsbad, S; Nielsen, OW; Sajadieh, A | 1 |
| Goričar, K; Janez, A; Jensterle, M; Kravos, NA | 1 |
| Hong, T; Hou, W; Ke, J; Liu, Y; Lu, R; Tian, Q; Wang, G; Wei, R; Yang, J | 1 |
| Shaw, E | 1 |
| Bi, Y; Chen, W; Feng, W; Gao, C; Li, P; Shen, S; Wu, M; Yin, T; Zhu, D | 1 |
| Jaffa, FM; Johnson, E; Kalyani, RR; Shubrook, JH; Skolnik, N | 1 |
| Hemmingsen, B; Metzendorf, MI; Richter, B; Sonne, DP | 1 |
| Grajower, MM; Kasher-Meron, M | 1 |
| Eleftheriadou, I; Grigoropoulou, P; Kokkinos, A; Liatis, S; Liberopoulos, E; Tentolouris, N | 1 |
| Hunt, B; Kragh, N; McConnachie, CC; Montagnoli, R; Rossi, MC; Valentine, WJ | 1 |
| Chandarana, K; Harris, S; Jaeckel, E; Jódar, E; Lingvay, I; Ranthe, MF | 1 |
| Dang-Tan, T; Gamble, C; Hunt, B; McConnachie, CC | 1 |
| Bjekić-Macut, J; Božić-Antić, I; Macut, D; Tziomalos, K | 1 |
| Eisner, F; Eller, K; Eller, P; Lind, A; Mader, JK; Pieber, TR; Plank, J; Schilcher, G; Schwetz, V | 1 |
| Chamberlain, JJ; Herman, WH; Kalyani, RR; Leal, S; Rhinehart, AS; Shubrook, JH; Skolnik, N | 1 |
| Angelucci, E; Bonadonna, RC; Cianfarani, S; Consoli, A; Davì, G; Di Castelnuovo, A; Federico, V; Guagnano, MT; Leo, M; Maccarone, MT; Manzoli, L; Santilli, F; Sborgia, C; Simeone, PG; Tartaro, A | 1 |
| Jiang, D; Li, M; Wang, Y; Yang, Y; Ying, M; Zhao, R | 1 |
| Chen, X; Jiang, X; Liu, Y | 1 |
| Eckel, RH; Koh, KK; Lim, S | 1 |
| Chen, CC; Chen, XM; Qiu, CM; Tian, Y; Wang, LF; Zhang, WQ | 1 |
| Janez, A; Jensterle, M; Salamun, V; Vrtacnik Bokal, E | 1 |
| Iogna Prat, L; Tsochatzis, EA | 1 |
| Hong, T; Ke, J; Liu, J; Lu, R; Tian, Q; Wei, R; Yang, J; Yu, F; Zhang, J | 1 |
| Bi, Y; Feng, WH; Gao, CX; Gao, LJ; Li, P; Shen, SM; Yang, DH; Yin, TT; Zhu, DL | 1 |
| López, M | 1 |
| Considine, RV; Goodwill, AG; Green, MA; Hamilton, L; Hutchins, GD; Mather, KJ; Mathias, C; Patel, NA; Territo, W; Tune, JD | 1 |
| Chefu, S; Filchenko, I; Kolpakova, M; Simanenkova, A; Vlasov, T | 1 |
| Abbas, NAT; El Salem, A | 1 |
| Deng, H; Dou, J; Hong, T; Huang, Q; Kang, Z; Kuang, H; Li, Y; Luo, S; Qin, G; Shan, Z; Tan, Y; Weng, J; Xiao, X; Xu, F; Xu, W; Yan, J; Yang, W; Yang, X; Yao, B; Yuan, H; Zeng, L | 1 |
| Hannallah, F; Hooda, A; Mehta, A | 1 |
| Weng, J | 1 |
| Upala, S | 1 |
| Digtiar, NI; Kaidashev, IP; Kaidasheva, EI; Savchenko, LG; Selikhova, LG; Shlykova, OA; Vesnina, LE | 1 |
| Cusi, K | 1 |
| Barrett, T; Barrientos-Pérez, M; Fainberg, U; Frimer-Larsen, H; Hafez, M; Hale, PM; Jalaludin, MY; Kovarenko, M; Libman, I; Lynch, JL; Rao, P; Shehadeh, N; Tamborlane, WV; Turan, S; Weghuber, D | 1 |
| Anholm, C; Boston, RC; Fenger, M; Haugaard, SB; Kristiansen, OP; Kumarathurai, P; Madsbad, S; Nielsen, OW; Pedersen, LR; Sajadieh, A; Samkani, A | 1 |
| Bi, Y; Qing, Z; Wang, X; Yang, QX; Zhang, B; Zhang, W; Zhang, X; Zhang, Z; Zhu, D | 1 |
| Anholm, C; Fenger, M; Haugaard, SB; Kristiansen, OP; Kumarathurai, P; Madsbad, S; Nielsen, OW; Pedersen, LR; Sajadieh, A; Samkani, A; Walzem, RL | 1 |
| Ben Nasr, M; Fiorina, P; Loretelli, C; Malvandi, AM; Zuccotti, GV | 1 |
| Aglialoro, A; Albanese, V; Albertelli, M; Boschetti, M; Ferone, D; Gatto, F; Minuto, M; Monachesi, M; Talco, M; Teti, C; Viviani, G | 1 |
| Capehorn, MS; Catarig, AM; Furberg, JK; Janez, A; Marre, M; Price, HC; Tadayon, S; Vergès, B | 1 |
| Taneja, V | 1 |
| Weng, J; Yan, J; Yang, D | 1 |
| Chen, G; Cheng, A; Chow, HM; Gao, Y; Herrup, K; Shi, M; So, RWL; Song, X; Zhang, J | 1 |
| Blazina, I; Selph, S | 1 |
| Abreu, M; Adams-Huet, B; Li, X; Lingvay, I; Patel, S; Tumyan, A | 1 |
| Bargiota, A; Billings, L; Cannon, AJ; Doshi, A; Hunt, B; Leiter, LA; Malkin, S; Mocarski, M; Ranthe, MF; Schiffman, A | 1 |
| Boccatonda, A; Cipollone, F; Consoli, A; Di Castelnuovo, A; Guagnano, MT; Liani, R; Santilli, F; Simeone, PG; Tripaldi, R; Vadini, F | 1 |
| Belousova, L; Blonde, L; Fainberg, U; Garcia-Hernandez, PA; Jain, SM; Kaltoft, MS; Mosenzon, O; Nafach, J; Palle, MS; Rea, R | 1 |
| Elkind-Hirsch, KE; Harris, R; Shaler, D | 1 |
| Andreadou, I; Balampanis, K; Bamias, A; Birba, D; Dimitriadis, G; Ikonomidis, I; Iliodromitis, E; Kalogeris, A; Katogiannis, K; Kountouri, A; Kousathana, F; Lambadiari, V; Parissis, J; Pavlidis, G; Thymis, J | 1 |
| Cena, H; Chiovato, L; Nappi, RE | 1 |
| Arnau Vives, MA; Ballesteros Martin-Portugués, A; Catalá Gregori, A; Caudet Esteban, J; Cerveró Rubio, A; Del Olmo-García, MI; Hervás Marín, D; Merino-Torres, JF; Penalba Martínez, M | 1 |
| Constantinidou, KG; Filippou, PK; Papaetis, GS; Stylianou, CS | 1 |
| Alexopoulos, AS; Buse, JB; Crowley, MJ; Jensen, TJ; McGuire, DK; Rasmussen, S; Saevereid, HA; Verma, S | 1 |
| Chi, CC; Lee, CY; Liu, CY; Tien O'Donnell, F; Tung, TH; Wang, SH | 1 |
| Guo, W; Lin, L; Tian, W; Xu, X | 1 |
| Bizino, MB; Geelhoed-Duijvestijn, PH; Jazet, IM; Kharagjitsingh, AV; Lamb, HJ; Paiman, EHM; Rensen, PCN; Smit, JW; van Eyk, HJ | 1 |
| Belzer, C; Cahen, DL; Davids, M; de Vos, WM; Fluitman, KS; Groen, AK; Herrema, H; Kramer, MHH; Nieuwdorp, M; Smits, MM; van Raalte, DH | 1 |
| Long, SA; Speake, C | 1 |
| Borshchev, Y; Galagudza, M; Karonova, T; Khalzova, A; Minasian, S; Samsonov, D; Shimshilashvili, A; Shpilevaya, O; Simanenkova, A; Timkina, N; Timofeeva, V; Vlasov, T | 1 |
| Bazarganipour, F; Jahanfar, S; Taghavi, SA; van Wely, M | 1 |
| Fu, BY; Wang, XJ | 1 |
| Arslanian, S; Atkinson, K; Barengolts, E; Brooks-Worrell, BM; Buchanan, TA; Edelstein, SL; Kahn, SE; Mather, KJ; Nadeau, KJ; Palmer, JP; Palomino, B; Tjaden, AH; Utzschneider, KM | 1 |
| Davis, SN; Siamashvili, M | 1 |
| Avgerinos, I; Bekiari, E; Karagiannis, T; Liakos, A; Tsapas, A | 1 |
| Balog, M; Drenjančević, I; Ducza, E; Gaspar, R; Heffer, M; Ivić, V; Matić, A; Seres, A; Szucs, KF; Vari, SG; Vuković, R | 1 |
| Bu, X; Gao, P; He, C; He, H; Jia, M; Li, Q; Li, Y; Liu, X; Sun, F; Yan, Z; Zhang, H; Zhao, Z; Zhou, X; Zhu, Z | 1 |
| Grøndahl, MFG; Johannesen, J; Knop, FK; Kristensen, K | 1 |
| Ge, JJ; Ge, WH; Shen, SM; Song, W; Wang, DJ | 1 |
| Allison, DC; Kaltoft, M; Lakkole, K; Panda, JK; Ramesh, C; Sargin, M; Smolyarchuk, E; Twine, M; Unger, J; Wolthers, B; Yarimbas, G; Zoghbi, M | 1 |
| Balog, M; Bota, I; Filipović, N; Gaspar, R; Grobe, M; Heffer, M; Ivić, V; Jerčić, L; Kretzschmar, G; Luetić, M; Tabi, T; Vari, SG; Vitlov Uljević, M; Vukojević, K; Zjalić, M | 1 |
| Hyötyläinen, T; Jendle, J; Nyström, T; Orešič, M | 1 |
| Boor, P; Buhl, EM; Ducza, E; Floege, J; Gaspar, R; Heffer, M; Ivic, V; Klinkhammer, BM; Lausberg, E; Seikrit, C; Seres, AB; Sztojkov-Ivanov, A; Szucs, K; Tabi, T; Vari, SG | 1 |
| Bi, Y; Cheng, H; Liu, J; Miao, Y; Ni, W; Wang, J; Zhang, B; Zhang, W; Zhang, Z | 1 |
| Al-Abdulrazzaq, D; Bishai, R; Carter, D; Doehring, O; Geller, D; Karoly, E; Monyak, J; Shehadeh, N; Sjöström, CD; Tamborlane, WV; Troja, T; Vazquez, EM | 1 |
| Chen, J; Dong, H; Liu, F; Yin, M; Zhang, Z | 1 |
| Cobelli, C; Dalla Man, C; Visentin, R | 1 |
| Karachaliou, F; Karavanaki, K; Paschou, SA; Soldatou, A; Tentolouris, N | 1 |
| Feng, Y; Ge, Y; He, Y; Hou, L; Huo, M; Ji, Y; Li, H; Liu, X; Liu, Y; Luo, Q; Qian, F; Wang, J; Wei, Y; Wu, S; Wu, Y; Xue, F; Yu, Y | 1 |
| Liu, H; Wu, F; Xie, Y; Yin, S; Zhang, Q; Zhao, G | 1 |
| He, B; Xing, C; Zhang, J; Zhao, H | 1 |
| Balasubramanyam, A; Burch, HB; Buse, JB; Butera, NM; Cohen, RM; Crandall, JP; Kahn, SE; Krause-Steinrauf, H; Lachin, JM; Larkin, ME; Nathan, DM; Rasouli, N; Tiktin, M; Wexler, DJ; Younes, N | 1 |
| Bebu, I; Burch, HB; Buse, JB; Cherrington, AL; Fortmann, SP; Green, JB; Kahn, SE; Kirkman, MS; Krause-Steinrauf, H; Lachin, JM; Larkin, ME; Nathan, DM; Phillips, LS; Pop-Busui, R; Steffes, M; Tiktin, M; Tripputi, M; Wexler, DJ; Younes, N | 1 |
| Abdelaal, M; Docherty, NG; Elliott, JA; Flatt, PR; Khan, D; Le Roux, CW; Moffett, CR; Naughton, V; Sridhar, A | 1 |
| Crown, W; Deng, Y; Dhruva, SS; Gandotra, C; Herrin, J; Lyon, TD; McCoy, RG; Noseworthy, P; Polley, EC; Quinto, K; Ross, JS; Shah, ND; Wallach, JD; Yao, X | 1 |
| Keskin, L; Yaprak, B | 1 |
| Cauchon, M; Lanthier, L; Mutchmore, A; Plourde, MÉ | 1 |
| Brown, K; Donato, AA | 1 |
| Baldini, G; Barger, SW; Griffin, H; Phelan, KD; Sullivan, SC | 1 |
| Long, Y; Zhang, Y | 1 |
| Ebell, MH | 1 |
| Fang, C; He, C; Huang, Y; Li, J; Sang, G; Tao, S; Zhou, B | 1 |
| Bica, IC; Diaconu, CT; Fierbinteanu Braticevici, C; Pantea Stoian, A; Pietroșel, VA; Salmen, T; Stoica, RA; Suceveanu, AI | 1 |
| Hao, YP; Meng, XM; Ren, RZ; Tang, YX; Yu, S; Yu, X | 1 |
| Dai, H; Hu, W; Li, K; Li, L; Liang, Z; Qiu, S; Wang, H; Wang, Y; Yang, G; Yang, M; Zhang, H; Zhang, L | 1 |
| Bebu, I; de Boer, IH; Ghosh, A; Inzucchi, SE; Ismail-Beigi, F; McGill, JB; Mudaliar, S; Schade, D; Steffes, MW; Tamborlane, WV; Tan, MH; Wexler, DJ; Younes, N | 1 |
| Atonal-Flores, B; Barranco-Juarez, A; León-Vázquez, ML | 1 |
| Hsiao, JL; Jeong, C; Masson, R; Shi, VY; Shih, T | 1 |
| Wu, Y; Yuan, S | 1 |
| Bagamery, F; Bakula, M; Balog, M; Berecki, M; Blažetić, S; Debeljak, Ž; Ducza, E; Fenrich, M; Gajović, S; Gaspar, R; Hajagos-Tóth, J; Heffer, M; Imširović, A; Ivić, V; Labak, I; Mahiiovych, S; Mandić, D; Rončević, A; Scitovski, R; Seres-Bokor, A; Szökő, É; Sztojkov-Ivanov, A; Szűcs, KF; Tábi, T; Vari, SG; Vuković, R; Zjalić, M | 1 |
48 review(s) available for metformin and liraglutide
| Article | Year |
|---|---|
Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials.
Topics: Body Mass Index; Diabetes Mellitus, Type 2; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Insulin; Liraglutide; Metformin; Placebos; Randomized Controlled Trials as Topic; Receptors, Glucagon; Sulfonylurea Compounds | 2009 |
[Liraglutide: a human GLP-1 analogue for the treatment of diabetes mellitus type 2].
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Liraglutide; Metformin; Thiazolidinediones | 2009 |
Managing highly insulin-resistant diabetes mellitus: weight loss approaches and medical management.
Topics: Amyloid; Bariatric Surgery; Diabetes Mellitus; Diet, Reducing; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Exercise; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Islet Amyloid Polypeptide; Liraglutide; Metformin; Obesity; Peptides; Thiazolidinediones; Treatment Failure; Venoms; Weight Loss | 2010 |
Early clinical studies with liraglutide.
Topics: Blood Glucose; Body Weight; Cardiotonic Agents; Cardiovascular Diseases; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Diabetes Mellitus, Type 2; Disease Management; Drug Therapy, Combination; Gastric Emptying; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Liraglutide; Metformin | 2010 |
Optimizing outcomes for GLP-1 agonists.
Topics: Algorithms; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Exenatide; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Liraglutide; Male; Metformin; Middle Aged; Peptides; Sulfonylurea Compounds; Treatment Outcome; Venoms | 2011 |
Liraglutide for the treatment of type 2 diabetes.
Topics: Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liraglutide; Meta-Analysis as Topic; Metformin; Multicenter Studies as Topic; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Weight Loss | 2011 |
Recent diabetes issues affecting the primary care clinician.
Topics: Adamantane; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Incretins; Liraglutide; Metformin; Primary Health Care; Rosiglitazone; Thiazolidinediones; Vitamin B 12 Deficiency | 2011 |
[Incretin-based therapy for treating patients with type 2 diabetes].
Topics: Adamantane; Body Mass Index; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Approval; Drug Therapy, Combination; Exenatide; Gliclazide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hungary; Hypoglycemic Agents; Incretins; Linagliptin; Liraglutide; Metformin; Nitriles; Peptides; Pioglitazone; Purines; Pyrazines; Pyrrolidines; Quinazolines; Receptors, Glucagon; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Triazoles; Venoms; Vildagliptin | 2011 |
The design of the liraglutide clinical trial programme.
Topics: Blood Glucose; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; Liraglutide; Male; Metformin; Peptides; Pyrazines; Randomized Controlled Trials as Topic; Rosiglitazone; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Triazoles; Venoms | 2012 |
Liraglutide: from clinical trials to clinical practice.
Topics: Administration, Oral; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemia; Hypoglycemic Agents; Injections, Subcutaneous; Liraglutide; Male; Metformin; Nausea; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; United States | 2012 |
Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liraglutide; Male; Metformin; Middle Aged; Sulfonylurea Compounds; Weight Loss | 2013 |
Alzheimer's disease and diabetes: new insights and unifying therapies.
Topics: Alzheimer Disease; Amyloid Precursor Protein Secretases; Aspartic Acid Endopeptidases; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Glucagon-Like Peptide 1; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypoglycemic Agents; Incidence; Liraglutide; Male; Metformin; Receptor, Insulin; Risk Factors; tau Proteins | 2013 |
Options for combination therapy in type 2 diabetes: comparison of the ADA/EASD position statement and AACE/ACE algorithm.
Topics: Algorithms; Carbamates; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incretins; Insulin; Liraglutide; Metformin; Peptides; Piperidines; Practice Guidelines as Topic; Receptors, Glucagon; Sulfonylurea Compounds; Thiazolidinediones; Venoms | 2013 |
[Treatment of type 2 diabetes mellitus--which role do GLP-1 receptor agonists play?].
Topics: Blood Glucose; Clinical Trials as Topic; Combined Modality Therapy; Diabetes Mellitus, Type 2; Diet, Diabetic; Drug Therapy, Combination; Exenatide; Exercise; Germany; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Guideline Adherence; Humans; Hypoglycemic Agents; Insulin; Liraglutide; Metformin; Peptides; Receptors, Glucagon; Treatment Failure; Venoms | 2011 |
[Twice-daily and weekly exenatide: clinical profile of two pioneer formulations in incretin therapy].
Topics: Delayed-Action Preparations; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Exenatide; Female; Gastrointestinal Diseases; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Incretins; Injections, Subcutaneous; Insulin; Insulin Glargine; Insulin, Long-Acting; Liraglutide; Male; Metformin; Peptides; Pioglitazone; Receptors, Glucagon; Thiazolidinediones; Venoms; Weight Loss | 2014 |
Dulaglutide: the newest GLP-1 receptor agonist for the management of type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Insulin; Liraglutide; Metformin; Peptides; Pioglitazone; Pyrazines; Receptors, Glucagon; Recombinant Fusion Proteins; Sitagliptin Phosphate; Thiazolidinediones; Triazoles; Venoms | 2015 |
Benefits of combination of insulin degludec and liraglutide are independent of baseline glycated haemoglobin level and duration of type 2 diabetes.
Topics: Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin, Long-Acting; Liraglutide; Male; Metformin; Middle Aged; Randomized Controlled Trials as Topic; Time Factors; Treatment Outcome | 2016 |
Achieving the composite endpoint of glycated haemoglobin <7.0%, no weight gain and no hypoglycaemia in the once-weekly dulaglutide AWARD programme.
Topics: Diabetes Mellitus, Type 2; Drug Administration Schedule; Exenatide; Female; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Liraglutide; Male; Metformin; Middle Aged; Peptides; Randomized Controlled Trials as Topic; Recombinant Fusion Proteins; Sitagliptin Phosphate; Treatment Outcome; Venoms; Weight Gain | 2016 |
GLP-1 Receptor Agonists: Practical Considerations for Clinical Practice.
Topics: Blood Glucose; Blood Pressure; Body Weight; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Insulin; Liraglutide; Metformin; Peptides; Recombinant Fusion Proteins; Risk Factors; Venoms | 2015 |
Efficacy and safety of dulaglutide in patients with type 2 diabetes: a meta-analysis and systematic review.
Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Exenatide; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Insulin; Insulin Glargine; Liraglutide; Metformin; Patient Safety; Peptides; Randomized Controlled Trials as Topic; Recombinant Fusion Proteins; Sitagliptin Phosphate; Treatment Outcome; Venoms | 2016 |
Hypothalamic AMPK: a canonical regulator of whole-body energy balance.
Topics: Adipose Tissue, Brown; Adipose Tissue, White; AMP-Activated Protein Kinases; Anti-Obesity Agents; Diabetes Mellitus, Type 2; Drug Discovery; Energy Metabolism; Feeding Behavior; Glucose; Homeostasis; Humans; Hypoglycemic Agents; Hypothalamus; Liraglutide; Metformin; Obesity; Signal Transduction; Sympathetic Nervous System; Thermogenesis | 2016 |
[Impact of glucagon-like peptide-1 receptor agonists on nasopharyngitis and upper respiratory tract infection among patients with type 2 diabetes: a network meta-analysis].
Topics: Bayes Theorem; Diabetes Mellitus, Type 2; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Humans; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Insulin; Liraglutide; Metformin; Nasopharyngitis; Peptides; Randomized Controlled Trials as Topic; Recombinant Fusion Proteins; Respiratory Tract Infections; Thiazolidinediones; Venoms | 2016 |
The efficacy and safety of liraglutide added to metformin in patients with diabetes: a meta-analysis of randomized controlled trials.
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liraglutide; Metformin; Randomized Controlled Trials as Topic | 2016 |
Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials.
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diarrhea; Drug Therapy, Combination; Exenatide; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Liraglutide; Metformin; Nausea; Peptides; Venoms; Vomiting | 2017 |
Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Fasting; Glucagon-Like Peptide 1; Glucose Intolerance; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Liraglutide; Metformin; Nitriles; Peptides; Pyrrolidines; Randomized Controlled Trials as Topic; Risk Factors; Venoms; Vildagliptin | 2017 |
Preventing progression from gestational diabetes mellitus to diabetes: A thought-filled review.
Topics: Adult; Diabetes Mellitus, Type 2; Diabetes, Gestational; Disease Progression; Female; Humans; Hypoglycemic Agents; Life Style; Liraglutide; Metformin; Pioglitazone; Pregnancy; Risk Factors; Thiazolidinediones | 2017 |
Update on Cardiovascular Effects of Older and Newer Anti-diabetic Medications.
Topics: Benzhydryl Compounds; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptides; Glucosides; Humans; Hypoglycemic Agents; Insulin; Liraglutide; Metformin; Pioglitazone; Sodium-Glucose Transporter 2 | 2018 |
MANAGEMENT OF ENDOCRINE DISEASE: Polycystic ovary syndrome and nonalcoholic fatty liver disease.
Topics: Female; Humans; Hypoglycemic Agents; Insulin Resistance; Liraglutide; Metformin; Non-alcoholic Fatty Liver Disease; Polycystic Ovary Syndrome | 2017 |
Efficacy and safety of liraglutide versus sitagliptin both in combination with metformin in patients with type 2 diabetes: A systematic review and meta-analysis.
Topics: Diabetes Mellitus, Type 2; Drug Monitoring; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liraglutide; Metformin; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Treatment Outcome | 2017 |
Clinical implications of current cardiovascular outcome trials with sodium glucose cotransporter-2 (SGLT2) inhibitors.
Topics: Albuminuria; Atherosclerosis; Benzhydryl Compounds; Body Weight; Canagliflozin; Cardiovascular Diseases; Cardiovascular System; Glucagon; Glucagon-Like Peptides; Glucosides; Heart Failure; Hemodynamics; Humans; Hypoglycemic Agents; Ketones; Lipids; Liraglutide; Metabolic Syndrome; Metformin; Non-alcoholic Fatty Liver Disease; Osmosis; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2018 |
The effect of antidiabetic medications on non-alcoholic fatty liver disease (NAFLD).
Topics: Humans; Hypoglycemic Agents; Liraglutide; Metformin; Non-alcoholic Fatty Liver Disease; Pioglitazone; Thiazolidinediones | 2018 |
Hypothalamic AMPK and energy balance.
Topics: Adipose Tissue, Brown; Adipose Tissue, White; AMP-Activated Protein Kinases; Animals; Anti-Obesity Agents; Antipsychotic Agents; Energy Metabolism; Feeding Behavior; Glucose; Homeostasis; Humans; Hypoglycemic Agents; Hypothalamus; Liraglutide; Liver; Metformin; Muscles; Nicotine; Nicotinic Agonists; Signal Transduction; Thermogenesis; Weight Gain | 2018 |
Diabetes drugs for nonalcoholic fatty liver disease: a systematic review.
Topics: Blood Glucose; Body Weight; Exenatide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liraglutide; Metformin; Non-alcoholic Fatty Liver Disease; Pioglitazone; Randomized Controlled Trials as Topic; Rosiglitazone | 2019 |
Obesity, Polycystic Ovary Syndrome, and Infertility: A New Avenue for GLP-1 Receptor Agonists.
Topics: Drug Therapy, Combination; Female; Glucagon-Like Peptide-1 Receptor; Humans; Incretins; Infertility, Female; Liraglutide; Metformin; Obesity; Polycystic Ovary Syndrome; Randomized Controlled Trials as Topic; Testosterone; Treatment Outcome; Weight Loss | 2020 |
Liraglutide: New Perspectives for the Treatment of Polycystic Ovary Syndrome.
Topics: Adult; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Liraglutide; Metformin; Middle Aged; Obesity; Overweight; Polycystic Ovary Syndrome; Weight Loss | 2020 |
Effects of antidiabetic drugs on psoriasis: A meta-analysis.
Topics: Humans; Hypoglycemic Agents; Liraglutide; Metformin; Pioglitazone; Psoriasis; Rosiglitazone; Treatment Outcome | 2021 |
Pharmacological and non-pharmacological strategies for obese women with subfertility.
Topics: Abortion, Spontaneous; Appetite Depressants; Bias; Carnitine; Clomiphene; Dexfenfluramine; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Infertility, Female; Life Style; Liraglutide; Live Birth; Mental Health; Metformin; Obesity; Pregnancy; Quality of Life; Randomized Controlled Trials as Topic; Weight Loss | 2021 |
Update on the effects of GLP-1 receptor agonists for the treatment of polycystic ovary syndrome.
Topics: Exenatide; Female; Glucagon-Like Peptide-1 Receptor; Heart Disease Risk Factors; Humans; Hypoglycemic Agents; Insulin Resistance; Liraglutide; Metformin; Polycystic Ovary Syndrome; Weight Loss | 2021 |
GLP-1 receptor agonists for cardiovascular outcomes with and without metformin. A systematic review and meta-analysis of cardiovascular outcomes trials.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Liraglutide; Metformin | 2021 |
Treatment of type 2 diabetes in children: what are the specific considerations?
Topics: Adolescent; Child; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Liraglutide; Metformin; Weight Loss | 2021 |
The effectiveness and safety of liraglutide in treating overweight/obese patients with polycystic ovary syndrome: a meta-analysis.
Topics: Drug Synergism; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Hypoglycemic Agents; Liraglutide; Medication Therapy Management; Metformin; Obesity; Polycystic Ovary Syndrome; Treatment Outcome | 2022 |
Type 2 diabetes in children and adolescents: distinct characteristics and evidence-based management.
Topics: Adolescent; Child; Diabetes Mellitus, Type 2; Humans; Insulin; Life Style; Liraglutide; Metformin | 2022 |
Comparative efficacy and safety of glucose-lowering drugs in children and adolescents with type 2 diabetes: A systematic review and network meta-analysis.
Topics: Adolescent; Adult; Child; Diabetes Mellitus, Type 2; Exenatide; Glucose; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Linagliptin; Liraglutide; Metformin; Network Meta-Analysis; Sitagliptin Phosphate | 2022 |
Comparison of weight loss and adverse events of obesity drugs in children and adolescents: a systematic review and meta-analysis.
Topics: Adolescent; Anti-Obesity Agents; Child; Exenatide; Humans; Liraglutide; Metformin; Obesity; Orlistat; Topiramate; Weight Loss | 2022 |
Liraglutide combined with metformin treatment for obese people with type 2 diabetes mellitus: a systematic review and meta-analysis.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Liraglutide; Metformin; Obesity | 2023 |
The Effects of Cardioprotective Antidiabetic Therapy on Microbiota in Patients with Type 2 Diabetes Mellitus-A Systematic Review.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Liraglutide; Metformin; Microbiota; Sodium-Glucose Transporter 2 Inhibitors | 2023 |
Hormonal Treatments in Hidradenitis Suppurativa: A Systematic Review.
Topics: Finasteride; Flutamide; Hidradenitis Suppurativa; Humans; Liraglutide; Metformin; Spironolactone | 2023 |
Effectiveness and cost-effectiveness of six GLP-1RAs for treatment of Chinese type 2 diabetes mellitus patients that inadequately controlled on metformin: a micro-simulation model.
Topics: Body Mass Index; Comorbidity; Computer Simulation; Cost of Illness; Cost-Benefit Analysis; Cost-Effectiveness Analysis; Diabetes Mellitus, Type 2; Drug Therapy, Combination; East Asian People; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Glycemic Control; Humans; Hypoglycemic Agents; Liraglutide; Metformin; Quality-Adjusted Life Years; Treatment Outcome | 2023 |
84 trial(s) available for metformin and liraglutide
| Article | Year |
|---|---|
Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes.
Topics: Adult; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Liraglutide; Male; Metformin; Middle Aged | 2006 |
Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liraglutide; Male; Metformin; Middle Aged; Obesity; Placebos; Safety; Sulfonylurea Compounds | 2009 |
Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD).
Topics: Adolescent; Adult; Aged; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Fasting; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liraglutide; Metformin; Middle Aged; Placebos; Safety; Thiazolidinediones; Young Adult | 2009 |
Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Liraglutide; Male; Metformin; Middle Aged; Placebos; Sulfonylurea Compounds; Young Adult | 2009 |
Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Liraglutide; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Failure; Treatment Outcome; Triazoles; Young Adult | 2010 |
Patient-reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add-on to metformin.
Topics: Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemia; Hypoglycemic Agents; Liraglutide; Male; Metformin; Middle Aged; Patient Satisfaction; Quality of Life; Sulfonylurea Compounds; Treatment Outcome | 2010 |
Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China, South Korea and India: a 16-week, randomized, doubl
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Asian People; Blood Pressure; China; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; India; Liraglutide; Male; Metformin; Middle Aged; Republic of Korea; Sulfonylurea Compounds; Weight Loss; Young Adult | 2011 |
Liraglutide improves treatment satisfaction in people with Type 2 diabetes compared with sitagliptin, each as an add on to metformin.
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liraglutide; Male; Metformin; Patient Satisfaction; Pyrazines; Quality of Life; Sitagliptin Phosphate; Surveys and Questionnaires; Treatment Outcome; Triazoles | 2011 |
One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fasting; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liraglutide; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Weight Loss | 2011 |
Addition of liraglutide in patients with Type 2 diabetes well controlled on metformin monotherapy improves several markers of vascular function.
Topics: Adult; Aged; Arginine; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; E-Selectin; Endothelium, Vascular; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Liraglutide; Male; Metformin; Microcirculation; Middle Aged; Plasminogen Activator Inhibitor 1; Proinsulin; Prospective Studies | 2012 |
Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Detemir; Insulin, Long-Acting; Liraglutide; Male; Metformin; Middle Aged | 2012 |
Efficacy and safety of switching from the DPP-4 inhibitor sitagliptin to the human GLP-1 analog liraglutide after 52 weeks in metformin-treated patients with type 2 diabetes: a randomized, open-label trial.
Topics: Adult; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Liraglutide; Metformin; Nausea; Patient Satisfaction; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2012 |
Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin.
Topics: Adult; Aged; C-Peptide; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Resistance; Female; Glucagon; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hyperglycemia; Hyperinsulinism; Hypoglycemic Agents; Incretins; Injections, Subcutaneous; Liraglutide; Male; Metformin; Middle Aged; Peptides | 2013 |
Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy with liraglutide in patients with type 2 diabetes mellitus inadequately controlled on metformin: a randomised clinical tri
Topics: Adolescent; Adult; Aged; Diabetes Mellitus, Type 2; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liraglutide; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome; Triazoles; Young Adult | 2013 |
Rationale and design of the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE).
Topics: Adult; Blood Glucose; Comparative Effectiveness Research; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; Liraglutide; Male; Metformin; Middle Aged; Outcome Assessment, Health Care; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Triazoles | 2013 |
Restoring Insulin Secretion (RISE): design of studies of β-cell preservation in prediabetes and early type 2 diabetes across the life span.
Topics: Adolescent; Adult; Aged; Arginine; Blood Glucose; C-Peptide; Child; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Gastroplasty; Glucagon-Like Peptide 1; Glucose Clamp Technique; Glucose Tolerance Test; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Insulin-Secreting Cells; Liraglutide; Male; Metformin; Middle Aged; Prediabetic State; Young Adult | 2014 |
Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin.
Topics: Adult; Body Weight; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Liraglutide; Metformin; Obesity; Receptors, Glucagon; Waist Circumference; Weight Loss | 2014 |
A randomized controlled trial comparing the GLP-1 receptor agonist liraglutide to a sulphonylurea as add on to metformin in patients with established type 2 diabetes during Ramadan: the Treat 4 Ramadan Trial.
Topics: Adult; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fasting; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Islam; Liraglutide; Male; Metformin; Middle Aged; Patient Satisfaction; Receptors, Glucagon; Sulfonylurea Compounds; Treatment Outcome; United Kingdom | 2014 |
A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON).
Topics: Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin Aspart; Insulin, Long-Acting; Liraglutide; Male; Metformin; Middle Aged; Treatment Outcome; Weight Loss | 2014 |
Management of hyperglycemia associated with pasireotide (SOM230): healthy volunteer study.
Topics: Adamantane; Adolescent; Adult; Blood Glucose; Cyclohexanes; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucagon; Glucagon-Like Peptide 1; Glucose Tolerance Test; Healthy Volunteers; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Liraglutide; Male; Maximum Tolerated Dose; Metformin; Middle Aged; Nateglinide; Nitriles; Phenylalanine; Prognosis; Pyrrolidines; Somatostatin; Vildagliptin; Young Adult | 2014 |
Efficacy and safety comparison of add-on therapy with liraglutide, saxagliptin and vildagliptin, all in combination with current conventional oral hypoglycemic agents therapy in poorly controlled Chinese type 2 diabetes.
Topics: Adamantane; Adult; Asian People; Blood Glucose; Body Weight; China; Diabetes Mellitus, Type 2; Dipeptides; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Liraglutide; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Treatment Outcome; Vildagliptin | 2014 |
Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial.
Topics: Analysis of Variance; Blood Glucose; Diabetes Mellitus, Type 2; Drug Administration Schedule; Fasting; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Liraglutide; Male; Metformin; Middle Aged; Recombinant Fusion Proteins; Treatment Outcome | 2014 |
Adding liraglutide to the backbone therapy of biguanide in patients with coronary artery disease and newly diagnosed type-2 diabetes (the AddHope2 study): a randomised controlled study protocol.
Topics: Coronary Artery Disease; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Liraglutide; Metformin; Research Design | 2014 |
Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDegLira).
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin, Long-Acting; Liraglutide; Male; Metformin; Middle Aged; Sulfonylurea Compounds; Treatment Outcome; Weight Loss | 2014 |
Comparison of insulin glargine and liraglutide added to oral agents in patients with poorly controlled type 2 diabetes.
Topics: Administration, Oral; Aged; Blood Glucose; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; International Cooperation; Liraglutide; Male; Metformin; Middle Aged; Treatment Outcome | 2015 |
Liraglutide reduces oxidative stress and restores heme oxygenase-1 and ghrelin levels in patients with type 2 diabetes: a prospective pilot study.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Ghrelin; Glucagon-Like Peptide 1; Heme Oxygenase-1; Humans; Hypoglycemic Agents; Liraglutide; Male; Metformin; Middle Aged; Oxidative Stress; Pilot Projects; Prospective Studies | 2015 |
Efficacy and safety of liraglutide monotherapy compared with metformin in Japanese overweight/obese patients with type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Japan; Liraglutide; Male; Metformin; Middle Aged; Obesity; Overweight; Weight Gain | 2015 |
Effects of Insulin Glargine and Liraglutide Therapy on Liver Fat as Measured by Magnetic Resonance in Patients With Type 2 Diabetes: A Randomized Trial.
Topics: Adipose Tissue; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fatty Liver; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; Liraglutide; Liver; Magnetic Resonance Imaging; Male; Metformin; Middle Aged | 2015 |
Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes on Optimized Insulin Glargine With or Without Metformin: A Randomized, Open-Label Trial.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Gastric Emptying; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin Glargine; Liraglutide; Male; Metformin; Middle Aged; Peptides; Postprandial Period; Treatment Outcome | 2015 |
One-year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26-week extension to a 26-week main trial.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fasting; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin, Long-Acting; Liraglutide; Male; Metformin; Middle Aged; Pioglitazone; Thiazolidinediones; Weight Loss | 2015 |
Short term monotherapy with GLP-1 receptor agonist liraglutide or PDE 4 inhibitor roflumilast is superior to metformin in weight loss in obese PCOS women: a pilot randomized study.
Topics: Adult; Aminopyridines; Benzamides; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Female; Glucagon-Like Peptide-1 Receptor; Humans; Liraglutide; Metformin; Obesity; Phosphodiesterase 4 Inhibitors; Polycystic Ovary Syndrome; Weight Loss | 2015 |
Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo-controlled trial.
Topics: Aged; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Fasting; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulins; Liraglutide; Male; Metformin; Middle Aged | 2015 |
[The efficacy and safety of human glucagon-like peptide-1 analogue liraglutide in newly diagnosed type 2 diabetes with glycosylated hemoglobin A1c > 9].
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; Liraglutide; Metformin; Treatment Outcome | 2015 |
Effect of liraglutide vs. NPH in combination with metformin on blood glucose fluctuations assessed using continuous glucose monitoring in patients with newly diagnosed type 2 diabetes.
Topics: Adult; Aged; Biomarkers; Blood Glucose; Body Mass Index; China; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Gastrointestinal Diseases; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin, Isophane; Liraglutide; Male; Metformin; Middle Aged; Monitoring, Ambulatory; Predictive Value of Tests; Prospective Studies; Time Factors; Treatment Outcome; Waist Circumference | 2015 |
Effects of Liraglutide Monotherapy on Beta Cell Function and Pancreatic Enzymes Compared with Metformin in Japanese Overweight/Obese Patients with Type 2 Diabetes Mellitus: A Subpopulation Analysis of the KIND-LM Randomized Trial.
Topics: Amylases; Blood Glucose; Body Fat Distribution; Body Weight; Diabetes Mellitus, Type 2; Drug Administration Schedule; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Insulin-Secreting Cells; Lipase; Liraglutide; Male; Metformin; Middle Aged; Obesity; Organ Size; Overweight; Radiography; Treatment Outcome | 2015 |
Liraglutide is effective and well tolerated in combination with an oral antidiabetic drug in Japanese patients with type 2 diabetes: A randomized, 52-week, open-label, parallel-group trial.
Topics: Administration, Oral; Aged; Asian People; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Japan; Liraglutide; Male; Metformin; Middle Aged; Treatment Outcome | 2016 |
Effect of adding insulin degludec to treatment in patients with type 2 diabetes inadequately controlled with metformin and liraglutide: a double-blind randomized controlled trial (BEGIN: ADD TO GLP-1 Study).
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Fasting; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin, Long-Acting; Liraglutide; Male; Metformin; Middle Aged; Treatment Outcome | 2016 |
Efficacy and safety of liraglutide versus sitagliptin, both in combination with metformin, in Chinese patients with type 2 diabetes: a 26-week, open-label, randomized, active comparator clinical trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anorexia; Asian People; Blood Glucose; Body Weight; China; Diabetes Mellitus, Type 2; Diarrhea; Drug Therapy, Combination; Fasting; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Liraglutide; Male; Metformin; Middle Aged; Nausea; Sitagliptin Phosphate; Treatment Outcome; Young Adult | 2016 |
Weight and Glucose Reduction Observed with a Combination of Nutritional Agents in Rodent Models Does Not Translate to Humans in a Randomized Clinical Trial with Healthy Volunteers and Subjects with Type 2 Diabetes.
Topics: Adolescent; Adult; Aged; Animals; Biological Factors; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Female; Glucagon-Like Peptide 1; Healthy Volunteers; Humans; Hypoglycemic Agents; Liraglutide; Male; Metformin; Mice; Mice, Inbred C57BL; Middle Aged; Weight Loss; Young Adult | 2016 |
[The effect of liraglutide in combination with human umbilical cord mesenchymal stem cells treatment on glucose metabolism and β cell function in type 2 diabetes mellitus].
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Glucose Tolerance Test; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Liraglutide; Mesenchymal Stem Cells; Metformin; Treatment Outcome; Umbilical Cord | 2016 |
Once-Daily Liraglutide Versus Lixisenatide as Add-on to Metformin in Type 2 Diabetes: A 26-Week Randomized Controlled Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Liraglutide; Male; Metformin; Middle Aged; Peptides; Postprandial Period; Treatment Outcome; Young Adult | 2016 |
Efficacy and safety of liraglutide compared to sulphonylurea during Ramadan in patients with type 2 diabetes (LIRA-Ramadan): a randomized trial.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Substitution; Drug Therapy, Combination; Fasting; Female; Humans; Hypoglycemic Agents; Islam; Liraglutide; Male; Metformin; Middle Aged; Sulfonylurea Compounds; Treatment Outcome | 2016 |
Efficacy and safety of switching from sitagliptin to liraglutide in subjects with type 2 diabetes (LIRA-SWITCH): a randomized, double-blind, double-dummy, active-controlled 26-week trial.
Topics: Adult; Aged; Aged, 80 and over; Asia; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Substitution; Drug Therapy, Combination; Europe; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Liraglutide; Male; Metformin; Middle Aged; Nausea; North America; Sitagliptin Phosphate; Treatment Outcome | 2016 |
Biliary effects of liraglutide and sitagliptin, a 12-week randomized placebo-controlled trial in type 2 diabetes patients.
Topics: Aged; Bile Acids and Salts; Blood Glucose; Chenodeoxycholic Acid; Cholic Acid; Deoxycholic Acid; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Fasting; Feces; Female; Gallbladder; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liraglutide; Male; Metformin; Middle Aged; Organ Size; Postprandial Period; Sitagliptin Phosphate; Sulfonylurea Compounds; Ultrasonography; Ursodeoxycholic Acid | 2016 |
Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon-like peptide-1 receptor agonist liraglutide: A randomized controlled trial in patients with type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Liraglutide; Male; Metformin; Middle Aged; Sitagliptin Phosphate; Treatment Outcome | 2017 |
Heart rate acceleration with GLP-1 receptor agonists in type 2 diabetes patients: an acute and 12-week randomised, double-blind, placebo-controlled trial.
Topics: Aged; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Method; Exenatide; Female; Glucagon-Like Peptide-1 Receptor; Heart Rate; Humans; Hypoglycemic Agents; Liraglutide; Male; Metformin; Middle Aged; Peptides; Sulfonylurea Compounds; Treatment Outcome; Venoms | 2017 |
Effects of Liraglutide on Heart Rate and Heart Rate Variability: A Randomized, Double-Blind, Placebo-Controlled Crossover Study.
Topics: Aged; Circadian Rhythm; Coronary Artery Disease; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Electrocardiography, Ambulatory; Female; Heart Rate; Humans; Hypoglycemic Agents; Liraglutide; Male; Metformin; Middle Aged; Overweight | 2017 |
Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: an 18-month prospective study.
Topics: Aged; Biomarkers; Carotid Artery Diseases; Carotid Intima-Media Thickness; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Echocardiography, Doppler, Color; Female; Humans; Hypoglycemic Agents; Incretins; Italy; Liraglutide; Male; Metabolic Syndrome; Metformin; Middle Aged; Predictive Value of Tests; Prevalence; Prospective Studies; Risk Factors; Treatment Outcome | 2016 |
Liraglutide causes large and rapid epicardial fat reduction.
Topics: Adipose Tissue; Adult; Body Mass Index; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Intra-Abdominal Fat; Liraglutide; Male; Metformin; Middle Aged; Pericardium; Risk Factors | 2017 |
Effects of the glucagon-like peptide-1 receptor agonist liraglutide on 24-h ambulatory blood pressure in patients with type 2 diabetes and stable coronary artery disease: a randomized, double-blind, placebo-controlled, crossover study.
Topics: Aged; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Coronary Artery Disease; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucagon-Like Peptide-1 Receptor; Heart Rate; Humans; Hypoglycemic Agents; Liraglutide; Male; Metformin; Middle Aged | 2017 |
Short-term effectiveness of low dose liraglutide in combination with metformin versus high dose liraglutide alone in treatment of obese PCOS: randomized trial.
Topics: Adult; Biomarkers; Blood Glucose; Body Weight; Drug Therapy, Combination; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liraglutide; Metformin; Obesity; Pilot Projects; Polycystic Ovary Syndrome; Prognosis; Prospective Studies; Waist Circumference; Weight Loss | 2017 |
Randomized trial comparing the effects of gliclazide, liraglutide, and metformin on diabetes with non-alcoholic fatty liver disease.
Topics: Adipose Tissue; Blood Glucose; Body Composition; Diabetes Mellitus, Type 2; Female; Gliclazide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liraglutide; Liver Function Tests; Male; Metformin; Middle Aged; Non-alcoholic Fatty Liver Disease | 2017 |
Long-term Cost-effectiveness of Two GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus in the Italian Setting: Liraglutide Versus Lixisenatide.
Topics: Body Mass Index; Cost-Benefit Analysis; Diabetes Complications; Diabetes Mellitus, Type 2; Female; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Italy; Life Expectancy; Liraglutide; Male; Metformin; Middle Aged; Peptides; Quality-Adjusted Life Years | 2017 |
Insulin degludec/liraglutide (IDegLira) was effective across a range of dysglycaemia and body mass index categories in the DUAL V randomized trial.
Topics: Anti-Obesity Agents; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Drug Combinations; Drug Monitoring; Drug Resistance, Multiple; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Incretins; Insulin Glargine; Insulin, Long-Acting; Liraglutide; Metformin; Obesity; Overweight; Weight Gain; Weight Loss | 2018 |
Effects of Liraglutide on Weight Loss, Fat Distribution, and β-Cell Function in Obese Subjects With Prediabetes or Early Type 2 Diabetes.
Topics: Adipocytes; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Female; Glucagon-Like Peptide 1; Glucose Tolerance Test; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin-Like Growth Factor I; Insulin-Like Growth Factor II; Insulin-Secreting Cells; Life Style; Liraglutide; Longitudinal Studies; Lost to Follow-Up; Male; Metformin; Middle Aged; Obesity; Prediabetic State; Risk Factors; Weight Loss | 2017 |
Liraglutide suppresses non-esterified free fatty acids and soluble vascular cell adhesion molecule-1 compared with metformin in patients with recent-onset type 2 diabetes.
Topics: Administration, Oral; Adult; Biomarkers; China; Diabetes Mellitus, Type 2; Down-Regulation; Fatty Acids, Nonesterified; Female; Humans; Hypoglycemic Agents; Incretins; Injections, Subcutaneous; Liraglutide; Male; Metformin; Time Factors; Treatment Outcome; Vascular Cell Adhesion Molecule-1 | 2018 |
Liraglutide increases IVF pregnancy rates in obese PCOS women with poor response to first-line reproductive treatments: a pilot randomized study.
Topics: Adult; Drug Therapy, Combination; Female; Fertilization in Vitro; Humans; Hypoglycemic Agents; Infertility, Female; Liraglutide; Metformin; Obesity; Ovulation Induction; Pilot Projects; Polycystic Ovary Syndrome; Pregnancy; Pregnancy Rate; Sperm Injections, Intracytoplasmic; Treatment Outcome | 2018 |
Effects of liraglutide, metformin and gliclazide on body composition in patients with both type 2 diabetes and non-alcoholic fatty liver disease: A randomized trial.
Topics: Adolescent; Adult; Aged; Biomarkers; Blood Glucose; Body Composition; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Gliclazide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liraglutide; Liver Function Tests; Male; Metformin; Middle Aged; Non-alcoholic Fatty Liver Disease; Prognosis; Prospective Studies; Young Adult | 2019 |
Combination GLP-1 and Insulin Treatment Fails to Alter Myocardial Fuel Selection vs. Insulin Alone in Type 2 Diabetes.
Topics: Adult; Blood Glucose; Coronary Circulation; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Heart; Humans; Hypoglycemic Agents; Insulin Detemir; Liraglutide; Male; Metformin; Middle Aged; Myocardium; Treatment Outcome | 2018 |
Liraglutide, Sitagliptin, and Insulin Glargine Added to Metformin: The Effect on Body Weight and Intrahepatic Lipid in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease.
Topics: Adult; Aged; Blood Glucose; Body Weight; Comorbidity; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Hypoglycemic Agents; Insulin Glargine; Linear Models; Lipid Metabolism; Liraglutide; Male; Metformin; Middle Aged; Multivariate Analysis; Non-alcoholic Fatty Liver Disease; Prognosis; Prospective Studies; Sitagliptin Phosphate; Treatment Outcome | 2019 |
Liraglutide in Children and Adolescents with Type 2 Diabetes.
Topics: Adolescent; Blood Glucose; Child; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Gastrointestinal Diseases; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Liraglutide; Male; Metformin | 2019 |
Effect of liraglutide on estimates of lipolysis and lipid oxidation in obese patients with stable coronary artery disease and newly diagnosed type 2 diabetes: A randomized trial.
Topics: Aged; Blood Glucose; Coronary Artery Disease; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Fatty Acids, Nonesterified; Female; Humans; Hypoglycemic Agents; Lipid Metabolism; Lipolysis; Liraglutide; Male; Metformin; Middle Aged; Obesity; Oxidation-Reduction; Treatment Outcome | 2019 |
Olfactory Dysfunction Mediates Adiposity in Cognitive Impairment of Type 2 Diabetes: Insights From Clinical and Functional Neuroimaging Studies.
Topics: Adiposity; Adult; Aged; Blood Glucose; Brain; Cognition; Cognitive Dysfunction; Diabetes Mellitus, Type 2; Exenatide; Female; Functional Neuroimaging; Glucagon-Like Peptide-1 Receptor; Humans; Insulin; Liraglutide; Magnetic Resonance Imaging; Male; Metformin; Middle Aged; Obesity; Olfaction Disorders; Olfactory Perception; Smell | 2019 |
Liraglutide in combination with metformin may improve the atherogenic lipid profile and decrease C-reactive protein level in statin treated obese patients with coronary artery disease and newly diagnosed type 2 diabetes: A randomized trial.
Topics: Aged; Biomarkers; Blood Glucose; C-Reactive Protein; Coronary Artery Disease; Cross-Over Studies; Denmark; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Inflammation Mediators; Lipids; Liraglutide; Male; Metformin; Middle Aged; Obesity; Time Factors; Treatment Outcome | 2019 |
Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10).
Topics: Administration, Oral; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Injections, Subcutaneous; Liraglutide; Male; Metformin; Middle Aged; Treatment Outcome | 2020 |
Effect of medication adherence on clinical outcomes in type 2 diabetes: analysis of the SIMPLE study.
Topics: Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Liraglutide; Male; Medication Adherence; Metformin; Middle Aged; Prognosis; Prospective Studies; Quality of Life | 2019 |
Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Basal Insulin and Basal-Bolus Therapy in Patients with Type 2 Diabetes Based on Attainment of Clinically Relevant Treatment Targets.
Topics: Adult; Blood Glucose; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Drug Combinations; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; Liraglutide; Metformin; United States | 2020 |
Liraglutide improves memory in obese patients with prediabetes or early type 2 diabetes: a randomized, controlled study.
Topics: Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Life Style; Liraglutide; Longitudinal Studies; Male; Memory; Metformin; Middle Aged; Neuropsychological Tests; Obesity; Prediabetic State; Psychometrics; Weight Loss | 2020 |
Liraglutide as add-on to sodium-glucose co-transporter-2 inhibitors in patients with inadequately controlled type 2 diabetes: LIRA-ADD2SGLT2i, a 26-week, randomized, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucose; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liraglutide; Male; Metformin; Middle Aged; Sodium; Sodium-Glucose Transporter 2 Inhibitors; Symporters; Treatment Outcome | 2020 |
Postpartum treatment with liraglutide in combination with metformin versus metformin monotherapy to improve metabolic status and reduce body weight in overweight/obese women with recent gestational diabetes: A double-blind, randomized, placebo-controlled
Topics: Adolescent; Adult; Diabetes, Gestational; Double-Blind Method; Drug Therapy, Combination; Energy Metabolism; Female; Humans; Liraglutide; Metformin; Middle Aged; Obesity; Overweight; Placebos; Postpartum Period; Pregnancy; Weight Loss; Young Adult | 2020 |
Effects of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12-Month Treatme
Topics: Adult; Aged; Arterial Pressure; Arteries; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Endothelial Cells; Female; Glucagon-Like Peptide-1 Receptor; Glucosides; Glycocalyx; Greece; Humans; Incretins; Insulin; Liraglutide; Male; Metformin; Middle Aged; Recovery of Function; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome; Vascular Stiffness; Ventricular Function, Left | 2020 |
Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and nonalcoholic fatty liver disease in twenty-six weeks: A randomized placebo-controlled trial.
Topics: Adult; Blood Glucose; Body Weight; China; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Intra-Abdominal Fat; Liraglutide; Liver; Male; Metformin; Middle Aged; Non-alcoholic Fatty Liver Disease; Obesity; Prospective Studies; Subcutaneous Fat; Treatment Outcome; Weight Loss | 2020 |
Liraglutide and sitagliptin have no effect on intestinal microbiota composition: A 12-week randomized placebo-controlled trial in adults with type 2 diabetes.
Topics: Adult; Aged; Bile Acids and Salts; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Gastrointestinal Microbiome; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liraglutide; Metformin; Middle Aged; RNA, Ribosomal, 16S; Sitagliptin Phosphate; Sulfonylurea Compounds | 2021 |
Islet Autoimmunity in Adults With Impaired Glucose Tolerance and Recently Diagnosed, Treatment Naïve Type 2 Diabetes in the Restoring Insulin SEcretion (RISE) Study.
Topics: Autoantibodies; Autoantigens; Autoimmunity; Diabetes Mellitus, Type 2; Glucose Intolerance; Humans; Hypoglycemic Agents; Insulin Glargine; Islets of Langerhans; Liraglutide; Metformin; T-Lymphocytes | 2021 |
Activation of Glucagon-Like Peptide-1 Receptor Ameliorates Cognitive Decline in Type 2 Diabetes Mellitus Through a Metabolism-Independent Pathway.
Topics: Biomarkers; Blood Glucose; Cognition; Cognitive Dysfunction; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Liraglutide; Male; Metformin; Middle Aged; Prefrontal Cortex; Prognosis; Prospective Studies | 2021 |
Maintenance of glycaemic control with liraglutide versus oral antidiabetic drugs as add-on therapies in patients with type 2 diabetes uncontrolled with metformin alone: A randomized clinical trial in primary care (LIRA-PRIME).
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Glycemic Control; Humans; Hypoglycemic Agents; Liraglutide; Metformin; Middle Aged; Primary Health Care; Treatment Outcome | 2022 |
Pharmacometabolomic profiles in type 2 diabetic subjects treated with liraglutide or glimepiride.
Topics: Aged; Biomarkers; Chromatography, High Pressure Liquid; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incretins; Lipidomics; Lipids; Liraglutide; Male; Metabolome; Metabolomics; Metformin; Middle Aged; Spectrometry, Mass, Electrospray Ionization; Sulfonylurea Compounds; Time Factors; Treatment Outcome | 2021 |
Enhancement of Impaired Olfactory Neural Activation and Cognitive Capacity by Liraglutide, but Not Dapagliflozin or Acarbose, in Patients With Type 2 Diabetes: A 16-Week Randomized Parallel Comparative Study.
Topics: Acarbose; Benzhydryl Compounds; Blood Glucose; Cognition; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liraglutide; Metformin | 2022 |
Once-Weekly Exenatide in Youth With Type 2 Diabetes.
Topics: Adolescent; Blood Glucose; Child; Diabetes Mellitus, Type 2; Exenatide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Liraglutide; Metformin; Peptides; Venoms | 2022 |
Effect of metformin versus metformin plus liraglutide on gonadal and metabolic profiles in overweight patients with polycystic ovary syndrome.
Topics: Female; Follicle Stimulating Hormone; Glucose; Humans; Liraglutide; Metabolome; Metformin; Obesity; Overweight; Polycystic Ovary Syndrome | 2022 |
Glycemia Reduction in Type 2 Diabetes - Glycemic Outcomes.
Topics: Blood Glucose; Comparative Effectiveness Research; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Liraglutide; Metformin; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome | 2022 |
Glycemia Reduction in Type 2 Diabetes - Microvascular and Cardiovascular Outcomes.
Topics: Albuminuria; Blood Glucose; Cardiovascular Diseases; Comparative Effectiveness Research; Diabetes Complications; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Drug Therapy, Combination; Dyslipidemias; Glomerular Filtration Rate; Glycated Hemoglobin; Heart Failure; Humans; Hypertension; Hypoglycemic Agents; Insulin Glargine; Liraglutide; Metformin; Microvessels; Sitagliptin Phosphate; Sulfonylurea Compounds | 2022 |
[Effect of Liraglutide on platelet distribution width and carotid intima-media thickness in type 2 diabetic mellitus patients with obesity].
Topics: Blood Glucose; Carotid Intima-Media Thickness; Diabetes Mellitus, Type 2; Female; Humans; Liraglutide; Male; Metformin; Obesity; Sulfonylurea Compounds | 2023 |
Comparative Effects of Glucose-Lowering Medications on Kidney Outcomes in Type 2 Diabetes: The GRADE Randomized Clinical Trial.
Topics: Adult; Albuminuria; Diabetes Mellitus, Type 2; Disease Progression; Female; Glomerular Filtration Rate; Glucose; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Kidney; Kidney Diseases; Liraglutide; Male; Metformin; Middle Aged; Sitagliptin Phosphate | 2023 |
76 other study(ies) available for metformin and liraglutide
| Article | Year |
|---|---|
Distinguishing among incretin-based therapies. Glucose-lowering effects of incretin-based therapies.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Resistance; Liraglutide; Male; Metformin; Middle Aged; Peptides; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms | 2010 |
Distinguishing among incretin-based therapies. Safety, tolerability, and nonglycemic effects of incretin-based therapies.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Incretins; Insulin; Liraglutide; Male; Metformin; Middle Aged; Peptides; Pyrazines; Receptors, Glucagon; Risk; Sitagliptin Phosphate; Triazoles; Venoms; Weight Loss | 2010 |
Distinguishing among incretin-based therapies. Patient education and self-management.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Resistance; Liraglutide; Male; Metformin; Middle Aged; Patient Education as Topic; Peptides; Pyrazines; Receptors, Glucagon; Self Care; Sitagliptin Phosphate; Triazoles; Venoms | 2010 |
Distinguishing among incretin-based therapies. Introduction.
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Exenatide; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Resistance; Insulin-Secreting Cells; Liraglutide; Metformin; Peptides; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms | 2010 |
Distinguishing among incretin-based therapies. Pathophysiology of type 2 diabetes mellitus: potential role of incretin-based therapies.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin-Secreting Cells; Liraglutide; Male; Metformin; Middle Aged; Peptides; Pyrazines; Severity of Illness Index; Sitagliptin Phosphate; Time Factors; Triazoles; Venoms | 2010 |
Results of a model analysis of the cost-effectiveness of liraglutide versus exenatide added to metformin, glimepiride, or both for the treatment of type 2 diabetes in the United States.
Topics: Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liraglutide; Male; Metformin; Middle Aged; Models, Econometric; Peptides; Quality-Adjusted Life Years; Statistics, Nonparametric; Sulfonylurea Compounds; United States; Venoms | 2010 |
Liraglutide therapy in Prader-Willi syndrome.
Topics: Adolescent; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Humans; Liraglutide; Metformin; Obesity, Morbid; Prader-Willi Syndrome; Treatment Outcome | 2011 |
Cost-utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to metformin monotherapy in Type 2 diabetes mellitus.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Body Mass Index; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Liraglutide; Male; Metformin; Middle Aged; Pyrazines; Quality-Adjusted Life Years; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome; Triazoles; United Kingdom; Young Adult | 2012 |
Incretin-based therapies in clinical practice: from efficacy to effectiveness. Focus on liraglutide.
Topics: Aged; Body Mass Index; Dipeptidyl Peptidase 4; Drug Monitoring; Drug Therapy, Combination; Exenatide; Female; Follow-Up Studies; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Liraglutide; Male; Metformin; Middle Aged; Outpatient Clinics, Hospital; Patient Acceptance of Health Care; Peptides; Retrospective Studies; Treatment Outcome; Venoms | 2012 |
Long-term clinical and economic outcomes associated with liraglutide versus sitagliptin therapy when added to metformin in the treatment of type 2 diabetes: a CORE Diabetes Model analysis.
Topics: Computer Simulation; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Liraglutide; Markov Chains; Metformin; Outcome Assessment, Health Care; Pyrazines; Quality-Adjusted Life Years; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2012 |
Cost-utility analysis of liraglutide versus glimepiride as add-on to metformin in type 2 diabetes patients in China.
Topics: China; Confidence Intervals; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucagon-Like Peptide 1; Health Care Costs; Humans; Hypoglycemic Agents; Life Expectancy; Liraglutide; Metformin; Models, Economic; Quality-Adjusted Life Years; Sulfonylurea Compounds | 2012 |
The role of medicinal chemistry in treating obesity, diabetes and metabolic syndrome.
Topics: Chemistry, Pharmaceutical; Diabetes Mellitus, Type 2; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Liraglutide; Metabolic Syndrome; Metformin; Obesity | 2013 |
Evaluating the short-term cost-effectiveness of liraglutide versus sitagliptin in patients with type 2 diabetes failing metformin monotherapy in the United States.
Topics: Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Drug Substitution; Glucagon-Like Peptide 1; Glycemic Index; Health Care Costs; Humans; Hypoglycemic Agents; Liraglutide; Metformin; Middle Aged; Pyrazines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Treatment Failure; Triazoles; United States | 2013 |
A prospective, claims-based assessment of the risk of pancreatitis and pancreatic cancer with liraglutide compared to other antidiabetic drugs.
Topics: Databases, Factual; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insurance Claim Reporting; Insurance, Health; Liraglutide; Male; Metformin; Pancreatic Neoplasms; Pancreatitis; Prospective Studies; Risk Assessment; Sulfonylurea Compounds; United States | 2014 |
Metformin and liraglutide ameliorate high glucose-induced oxidative stress via inhibition of PKC-NAD(P)H oxidase pathway in human aortic endothelial cells.
Topics: Acridines; Aorta; Binding Sites; Cells, Cultured; Diglycerides; Endothelial Cells; Glucagon-Like Peptide 1; Glucose; Humans; Hypoglycemic Agents; Liraglutide; Luminescence; Metformin; NADPH Oxidases; Oxidative Stress; Phosphorylation; Plasmids; Protein Kinase C; Protein Kinase C beta; Reactive Oxygen Species | 2014 |
[Liraglutide in polycystic ovary syndrome].
Topics: Adult; Diabetes Mellitus, Type 2; Drug Synergism; Female; Glucagon-Like Peptide 1; Hirsutism; Humans; Hypoglycemic Agents; Liraglutide; Menstrual Cycle; Metformin; Obesity, Morbid; Polycystic Ovary Syndrome; Testosterone; Weight Loss | 2014 |
GLP-1 agonism stimulates brown adipose tissue thermogenesis and browning through hypothalamic AMPK.
Topics: Adipose Tissue, Brown; Adult; Aged; Aged, 80 and over; AMP-Activated Protein Kinase Kinases; Animals; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Eating; Energy Metabolism; Exenatide; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Hypothalamus; Liraglutide; Male; Metformin; Mice; Middle Aged; Obesity; Peptides; Protein Kinases; Rats; Thermogenesis; Venoms; Young Adult | 2014 |
Cost-effectiveness of add-on treatments to metformin in a Swedish setting: liraglutide vs sulphonylurea or sitagplitin.
Topics: Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Health Services; Humans; Hypoglycemic Agents; Life Expectancy; Liraglutide; Male; Metformin; Middle Aged; Models, Economic; Pyrazines; Quality-Adjusted Life Years; Sitagliptin Phosphate; Smoking; Sulfonylurea Compounds; Sweden; Triazoles | 2014 |
Is insulin the most effective injectable antihyperglycaemic therapy?
Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Exenatide; Fasting; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; Liraglutide; Male; Metformin; Middle Aged; Peptides; Treatment Outcome; Venoms | 2015 |
Effect of bariatric surgery combined with medical therapy versus intensive medical therapy or calorie restriction and weight loss on glycemic control in Zucker diabetic fatty rats.
Topics: Age Factors; Animals; Behavior, Animal; Biomarkers; Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Disease Models, Animal; Drug Therapy, Combination; Eating; Feeding Behavior; Gastrectomy; Gastric Bypass; Glucagon-Like Peptide 1; Hypoglycemia; Hypoglycemic Agents; Insulin; Liraglutide; Male; Metformin; Obesity; Rats, Zucker; Risk Factors; Time Factors; Weight Gain; Weight Loss | 2015 |
Effects of Teraphy with Basal Insulin Analogues Combined with GLP 1 Analogues and Metformin in the Treatment of Obese Patients with Poorly Regulated Postprandial Glycemia.
Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycemic Index; Humans; Hypoglycemic Agents; Insulin, Long-Acting; Liraglutide; Male; Metformin; Middle Aged; Obesity; Postprandial Period | 2014 |
Correlation between baseline characteristics and clinical outcomes in a large population of diabetes patients treated with liraglutide in a real-world setting in Italy.
Topics: Aged; Blood Glucose; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Italy; Lipids; Liraglutide; Male; Metformin; Middle Aged; Retrospective Studies | 2015 |
Add-On Treatment with Liraglutide Improves Glycemic Control in Patients with Type 2 Diabetes on Metformin Therapy.
Topics: Aged; Blood Glucose; Blood Glucose Self-Monitoring; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fasting; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liraglutide; Male; Metformin; Middle Aged; Retrospective Studies; Sex Factors; Sulfonylurea Compounds; Treatment Outcome; Waist Circumference | 2015 |
The influence of age and metformin treatment status on reported gastrointestinal side effects with liraglutide treatment in type 2 diabetes.
Topics: Adult; Age Factors; Aged; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Gastrointestinal Diseases; Humans; Hypoglycemic Agents; Liraglutide; Male; Metformin; Middle Aged; Retrospective Studies; Risk Factors; Treatment Outcome; United Kingdom | 2015 |
The effects of insulin and liraglutide on osteoprotegerin and vascular calcification in vitro and in patients with type 2 diabetes.
Topics: Aged; Alkaline Phosphatase; Cells, Cultured; Core Binding Factor Alpha 1 Subunit; Coronary Vessels; Diabetes Mellitus, Type 2; Endpoint Determination; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; In Vitro Techniques; Insulin Glargine; Insulin, Long-Acting; Liraglutide; Male; Metformin; Middle Aged; Muscle, Smooth, Vascular; Osteoprotegerin; Pilot Projects; Prospective Studies; Sialoglycoproteins; Vascular Calcification | 2015 |
[Optimizing treatment of type 2 diabetic patients].
Topics: Administration, Oral; Diabetes Mellitus, Type 2; Drug Combinations; Germany; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Injections, Subcutaneous; Insulin, Long-Acting; Liraglutide; Metformin | 2015 |
Adding liraglutide to lifestyle changes, metformin and testosterone therapy boosts erectile function in diabetic obese men with overt hypogonadism.
Topics: Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Erectile Dysfunction; Glycated Hemoglobin; Hormone Replacement Therapy; Humans; Hypoglycemic Agents; Hypogonadism; Incretins; Liraglutide; Male; Metformin; Middle Aged; Obesity; Penile Erection; Retrospective Studies; Risk Reduction Behavior; Testosterone; Time Factors; Treatment Outcome; Weight Loss | 2015 |
Liraglutide vs. sitagliptin add-on to metformin treatment for type 2 diabetes mellitus: Short-term cost-per-controlled patient in Italy.
Topics: Biomarkers; Blood Glucose; Cost Savings; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Costs; Drug Substitution; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Italy; Liraglutide; Meta-Analysis as Topic; Metformin; Models, Economic; National Health Programs; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Time Factors; Treatment Outcome | 2016 |
Effect of incretin therapies compared to pioglitazone and gliclazide in non-alcoholic fatty liver disease in diabetic patients not controlled on metformin alone: An observational, pilot study.
Topics: Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Gliclazide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Lipids; Liraglutide; Liver Function Tests; Male; Metabolic Syndrome; Metformin; Middle Aged; Non-alcoholic Fatty Liver Disease; Peptides; Pilot Projects; Pioglitazone; Prospective Studies; Sitagliptin Phosphate; Thiazolidinediones; Venoms; Waist Circumference | 2016 |
Drug Combo Adds No Benefit in Patients with Type 2 Diabetes.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Drug Therapy, Combination; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Liraglutide; Metformin; Sitagliptin Phosphate | 2016 |
Euglycaemic diabetic ketoacidosis in a patient with type 2 diabetes started on empagliflozin.
Topics: Adult; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemic Agents; Insulin; Liraglutide; Male; Metformin; Pioglitazone; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiazolidinediones | 2016 |
Long-Term Effectiveness and Cost-Effectiveness of Metformin Combined with Liraglutide or Exenatide for Type 2 Diabetes Mellitus Based on the CORE Diabetes Model Study.
Topics: Adult; Asian People; China; Computer Simulation; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Exenatide; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Life Expectancy; Liraglutide; Male; Metformin; Middle Aged; Peptides; Quality-Adjusted Life Years; Survival Analysis; Time Factors; Treatment Outcome; Venoms | 2016 |
Euglycemic Ketoacidosis Caused by Sodium-Glucose Cotransporter 2 Inhibitors: A Case Report.
Topics: Adult; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Ketosis; Liraglutide; Metformin; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
Synergistic effects of metformin with liraglutide against endothelial dysfunction through GLP-1 receptor and PKA signalling pathway.
Topics: AMP-Activated Protein Kinases; Animals; Apolipoproteins E; Cyclic AMP-Dependent Protein Kinases; Diet, High-Fat; Drug Synergism; Glucagon-Like Peptide-1 Receptor; Human Umbilical Vein Endothelial Cells; Humans; Liraglutide; Male; Metformin; Mice; Mice, Knockout; Nitric Oxide Synthase Type III; Palmitic Acid; Reactive Oxygen Species; RNA Interference; RNA, Small Interfering; Signal Transduction | 2017 |
Should family physicians prescribe medication for obesity? NO.
Topics: Anti-Obesity Agents; Body Mass Index; Family Practice; Humans; Lactones; Liraglutide; Male; Metformin; Obesity; Orlistat; Practice Guidelines as Topic; Practice Patterns, Physicians' | 2017 |
Reducing CV risk in diabetes: An ADA update.
Topics: Antihypertensive Agents; Aspirin; Benzhydryl Compounds; Cardiovascular Diseases; Contraindications; Creatinine; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Drug Chronotherapy; Ezetimibe; Fenofibrate; Glucosides; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Hypoglycemic Agents; Hypolipidemic Agents; Life Style; Liraglutide; Metformin; Niacin; PCSK9 Inhibitors; Platelet Aggregation Inhibitors; Risk Reduction Behavior; Thiazolidinediones | 2017 |
Evaluating the short-term cost-effectiveness of liraglutide versus lixisenatide in patients with type 2 diabetes in the United States.
Topics: Blood Pressure; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Drug Combinations; Glycated Hemoglobin; Health Expenditures; Humans; Hypoglycemic Agents; Liraglutide; Metformin; Peptides; United States; Weight Gain | 2017 |
Combined metformin-associated lactic acidosis and euglycemic ketoacidosis.
Topics: Acidosis, Lactic; Aged; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Gluconeogenesis; Humans; Insulin; Ketosis; Kidney Failure, Chronic; Liraglutide; Male; Metformin | 2017 |
Treatment of Type 1 Diabetes: Synopsis of the 2017 American Diabetes Association Standards of Medical Care in Diabetes.
Topics: Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 1; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Islet Amyloid Polypeptide; Liraglutide; Metformin | 2017 |
Liraglutide and Metformin alone or combined therapy for type 2 diabetes patients complicated with coronary artery disease.
Topics: Adult; Aged; Blood Glucose; Coronary Artery Disease; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Liraglutide; Male; Metformin; Middle Aged; Pilot Projects; Treatment Outcome | 2017 |
Synergistic anti-tumor effects of liraglutide with metformin on pancreatic cancer cells.
Topics: AMP-Activated Protein Kinases; bcl-2-Associated X Protein; Caspase 3; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Drug Synergism; Humans; Hypoglycemic Agents; Liraglutide; Metformin; Pancreatic Neoplasms; Phosphorylation | 2018 |
Neuroprotective effect of glucagon-like peptide-1 receptor agonist is independent of glycaemia normalization in type two diabetic rats.
Topics: Animals; Blood Glucose; Brain; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glucagon-Like Peptide-1 Receptor; Hypoglycemic Agents; Ischemic Attack, Transient; Liraglutide; Male; Metformin; Neuroprotective Agents; Rats, Wistar | 2018 |
Metformin, sitagliptin, and liraglutide modulate serum retinol-binding protein-4 level and adipocytokine production in type 2 diabetes mellitus rat model.
Topics: Adipokines; Animals; Blood Glucose; Body Mass Index; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Models, Animal; Insulin Resistance; Lipids; Liraglutide; Male; Metformin; Rats; Rats, Wistar; Retinol-Binding Proteins; Sitagliptin Phosphate; Streptozocin | 2018 |
Metformin-associated lactic acidosis precipitated by liraglutide use: adverse effects of aggressive antihyperglycaemic therapy.
Topics: Acidosis, Lactic; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug-Related Side Effects and Adverse Reactions; Glycated Hemoglobin; Heart Arrest; Hemodiafiltration; Humans; Hypoglycemic Agents; Iatrogenic Disease; Insulin; Liraglutide; Male; Metformin; Treatment Outcome | 2018 |
Reply.
Topics: Body Weight; Diabetes Mellitus, Type 2; Humans; Insulin Glargine; Lipids; Liraglutide; Metformin; Non-alcoholic Fatty Liver Disease; Sitagliptin Phosphate | 2019 |
Letter to Editor: Role of Pharmacotherapy in Patients With Coexisting Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus.
Topics: Body Weight; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Glargine; Lipids; Liraglutide; Metformin; Non-alcoholic Fatty Liver Disease; Sitagliptin Phosphate | 2019 |
Liraglutide exerts an anti-inflammatory action in obese patients with type 2 diabetes.
Topics: Actins; Ceruloplasmin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Gene Expression; Humans; Hypoglycemic Agents; I-kappa B Proteins; Inflammation; Interleukin-2; Leukocytes, Mononuclear; Liraglutide; Male; Metformin; Middle Aged; NF-kappa B; Nod1 Signaling Adaptor Protein; Obesity; Pilot Projects; Prospective Studies; RNA, Messenger; Signal Transduction; Sirtuin 1; Sulfonylurea Compounds; Toll-Like Receptor 2; Toll-Like Receptor 4; Tumor Necrosis Factor-alpha | 2019 |
Incretin-Based Therapies for the Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes.
Topics: Body Weight; Diabetes Mellitus, Type 2; Humans; Incretins; Insulin Glargine; Lipids; Liraglutide; Metformin; Non-alcoholic Fatty Liver Disease; Sitagliptin Phosphate | 2019 |
Lack of Durable Improvements in β-Cell Function Following Withdrawal of Pharmacological Interventions in Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes.
Topics: Adult; Arginine; B-Lymphocytes; Blood Glucose; Body Weight; C-Peptide; Diabetes Mellitus, Type 2; Fasting; Female; Glucose Intolerance; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin Resistance; Liraglutide; Male; Metformin; Middle Aged; Withholding Treatment | 2019 |
Sitagliptin favorably modulates immune-relevant pathways in human beta cells.
Topics: Cell Line; Diabetes Mellitus, Type 2; Gene Expression; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Immunologic Factors; Inflammation; Insulin-Secreting Cells; Interleukin-6; Liraglutide; Metformin; Signal Transduction; Sitagliptin Phosphate; Tumor Necrosis Factor-alpha; Up-Regulation | 2019 |
Dipeptidyl peptidase-4 inhibitors do not alter GH/IGF-I axis in adult diabetic patients.
Topics: Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Human Growth Hormone; Humans; Hypoglycemic Agents; Insulin-Like Growth Factor I; Liraglutide; Male; Metformin; Middle Aged | 2020 |
Letter to the Editor: Intrahepatic Lipid Content After Insulin Glargine Addition to Metformin in Type II Diabetes Mellitus With Nonalcoholic Fatty Liver Disease.
Topics: Body Weight; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Glargine; Lipids; Liraglutide; Metformin; Non-alcoholic Fatty Liver Disease; Sitagliptin Phosphate | 2020 |
Reply.
Topics: Body Weight; Diabetes Mellitus, Type 2; Humans; Insulin Glargine; Lipids; Liraglutide; Metformin; Non-alcoholic Fatty Liver Disease; Sitagliptin Phosphate | 2020 |
Age-related hyperinsulinemia leads to insulin resistance in neurons and cell-cycle-induced senescence.
Topics: Aging; Animals; beta Catenin; Cell Cycle; Cell Death; Cellular Senescence; Cyclin-Dependent Kinase 5; Excitatory Postsynaptic Potentials; Gene Expression; Glycolysis; Hexokinase; Hyperinsulinism; Inhibitory Postsynaptic Potentials; Insulin; Insulin Resistance; Liraglutide; Male; Maze Learning; Metformin; Mice; Neurons; Phosphotransferases; Primary Cell Culture; Protein Serine-Threonine Kinases; Ubiquitination | 2019 |
Glycemic variability in type 2 diabetes mellitus and acute coronary syndrome: liraglutide compared with insulin glargine: a pilot study.
Topics: Acute Coronary Syndrome; Adult; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Glycemic Index; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Glargine; Liraglutide; Male; Metformin; Middle Aged; Pilot Projects; Random Allocation; Spain | 2020 |
Effects of Liraglutide on Cardiovascular Outcomes in Type 2 Diabetes Patients With and Without Baseline Metformin Use: Post Hoc Analyses of the LEADER Trial.
Topics: Adult; Aged; Cardiovascular Diseases; Cardiovascular System; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Therapy, Combination; Female; Hospitalization; Humans; Hypoglycemic Agents; Liraglutide; Male; Metformin; Middle Aged; Prevalence; Prognosis; Randomized Controlled Trials as Topic; Retrospective Studies; Treatment Outcome | 2020 |
Efficacy of liraglutide on glycemic endpoints in people of Western European and South Asian descent with T2DM using multiple daily insulin injections: results of the MAGNA VICTORIA studies.
Topics: Adolescent; Adult; Aged; Asia; Blood Glucose; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Europe; Female; Follow-Up Studies; Glycated Hemoglobin; Glycemic Control; Humans; Hypoglycemic Agents; Injections, Subcutaneous; Insulin; Liraglutide; Male; Metformin; Middle Aged; Netherlands; Placebos; Randomized Controlled Trials as Topic; Retrospective Studies; Treatment Outcome; Young Adult | 2021 |
Combination therapy in recent-onset type 1 diabetes.
Topics: Adult; Diabetes Mellitus, Type 1; Double-Blind Method; Humans; Hypoglycemic Agents; Liraglutide; Metformin | 2021 |
Comparative evaluation of metformin and liraglutide cardioprotective effect in rats with impaired glucose tolerance.
Topics: Animals; Biomarkers; Blood Glucose; Body Weight; Cardiotonic Agents; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Eating; Glucose Intolerance; Heart Function Tests; Hypoglycemic Agents; Liraglutide; Metformin; Myocardial Infarction; Rats; Treatment Outcome | 2021 |
The role of nursing care in the type 2 diabetes treatment associated with chronic liver diseases.
Topics: Diabetes Mellitus, Type 2; Exenatide; Gliclazide; Humans; Hypoglycemic Agents; Liraglutide; Metformin; Non-alcoholic Fatty Liver Disease; Pioglitazone; Sitagliptin Phosphate | 2022 |
Sex differences in oxidative stress level and antioxidative enzymes expression and activity in obese pre-diabetic elderly rats treated with metformin or liraglutide.
Topics: Animals; Antioxidants; Catalase; Female; Glutathione Peroxidase; Liraglutide; Male; Metformin; Obesity; Oxidative Stress; Prediabetic State; Rats; Rats, Sprague-Dawley; Sex Characteristics; Superoxide Dismutase | 2021 |
Sex-specific effects of metformin and liraglutide on renal pathology and expression of connexin 45 and pannexin 1 following long-term high-fat high-sugar diet.
Topics: Animals; Connexins; Diet, High-Fat; Dietary Carbohydrates; Female; Gene Expression Regulation; Kidney; Liraglutide; Male; Metformin; Nerve Tissue Proteins; Rats; Rats, Sprague-Dawley; Sex Characteristics; Time Factors | 2021 |
A Hypercaloric Diet Induces Early Podocyte Damage in Aged, Non-Diabetic Rats.
Topics: Animals; Diet, High-Fat; Female; Kidney Diseases; Liraglutide; Male; Metabolic Syndrome; Metformin; Obesity; Podocytes; Rats; Rats, Sprague-Dawley | 2021 |
Effects of Metformin on Renal Function, Cardiac Function, and Inflammatory Response in Diabetic Nephropathy and Its Protective Mechanism.
Topics: C-Reactive Protein; Diabetes Mellitus; Diabetic Nephropathies; Humans; Interleukin-6; Kidney; Liraglutide; Metformin; Stroke Volume; Tumor Necrosis Factor-alpha; Ventricular Function, Left | 2022 |
A software interface for in silico testing of type 2 diabetes treatments.
Topics: Blood Glucose; C-Peptide; Computer Simulation; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Liraglutide; Metformin; Software | 2022 |
Differential effects of RYGB surgery and best medical treatment for obesity-diabetes on intestinal and islet adaptations in obese-diabetic ZDSD rats.
Topics: Animals; Blood Glucose; Diabetes Mellitus; Fenofibrate; Gastric Bypass; Glucagon; Glucagon-Like Peptide 1; Insulin; Liraglutide; Male; Metformin; Obesity; Ramipril; Rats; Rats, Sprague-Dawley; Rats, Zucker; Rosuvastatin Calcium; Somatostatin | 2022 |
Emulating the GRADE trial using real world data: retrospective comparative effectiveness study.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Liraglutide; Metformin; Prospective Studies; Randomized Controlled Trials as Topic; Retrospective Studies; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome | 2022 |
Comparison of the effect of liraglutide and metformin therapy on the disease regulation and weight loss in obese patients with Type 2 diabetes mellitus.
Topics: Blood Glucose; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liraglutide; Metformin; Obesity; Triglycerides; Weight Loss | 2022 |
[In patients with type 2 diabetes on metformin, the addition of which antihyperglycemic class among a sulfonylurea (glimepiride), a DPP-4 inhibitor (sitagliptin), a GLP-1 agonist (liraglutide), or basal insulin (glargine) is the most effective to achieve
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucagon-Like Peptide 1; Glycemic Control; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Liraglutide; Metformin; Sitagliptin Phosphate; Treatment Outcome | 2023 |
In type 2 diabetes, glargine and liraglutide each improved glycemic outcomes at 5 y vs. glimepiride or sitagliptin.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin Glargine; Liraglutide; Metformin; Sitagliptin Phosphate; Treatment Outcome | 2023 |
Liraglutide Counteracts Endoplasmic Reticulum Stress in Palmitate-Treated Hypothalamic Neurons without Restoring Mitochondrial Homeostasis.
Topics: Animals; Endoplasmic Reticulum Stress; Hypothalamus; Liraglutide; Metformin; Mice; Mitochondria; Neurons; Palmitates | 2022 |
Liraglutide Is Probably the Best Second Drug to Prevent Cardiovascular Events in Patients With Type 2 Diabetes Mellitus Who Take Metformin.
Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Liraglutide; Metformin; Treatment Outcome | 2023 |
[Comparison of therapeutic effect of metformin hydrochloride/vildagliptin and liraglutide on type 2 diabetes mellitus in obese patients].
Topics: Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liraglutide; Metformin; Obesity; Retrospective Studies; Treatment Outcome; Vildagliptin | 2023 |
Hedgehog interacting protein as a circulating biomarker in women with obesity: a cross-sectional study and intervention studies.
Topics: Biomarkers; Blood Glucose; Cohort Studies; Cross-Sectional Studies; Female; Hedgehog Proteins; Humans; Insulin; Insulin Resistance; Liraglutide; Metformin; Obesity | 2023 |
[Indicators of diabetes mellitus after liraglutide, sitagliptin/metformin, linagliptin, and sitagliptin].
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucose; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Linagliptin; Liraglutide; Longitudinal Studies; Male; Metformin; Sitagliptin Phosphate; Treatment Outcome | 2023 |
Elderly rats fed with a high-fat high-sucrose diet developed sex-dependent metabolic syndrome regardless of long-term metformin and liraglutide treatment.
Topics: Aged; Animals; Female; Hypoglycemic Agents; Liraglutide; Male; Metabolic Syndrome; Metformin; Rats; Rats, Sprague-Dawley; Sucrose | 2023 |